August 10, 2011 -- KangLaiTe USA today disclosed an interim analysis for the company’s randomized, multi-centric phase 2 US trial in patients with advanced pancreatic cancer. Based on blinded, centralized CT readings,KLTi,the company’s lead product, when combined with gemcitbine achieved statistically significant superiority to gemcitabine alone for progression free survival, with notable associated symptomatic relief, at the lowest dose tested.
“We are very encouraged heading into the high dose cohort.” a company spokesman noted.
KLT-USA will soon launch additional US trials,including two with KLTi in palliation of cancer, and a low dose/high dose comparison for KLTc, the oral dose form, in previously treated prostate cancer patients with rising PSA.
The company is the US subsidiary of a Chinese pharmaceutical company, Zheijiang Kanglaite. KLTi and KLTc were developed from a traditional Chinese medicine, and have been on the market in China for several years for treatment of NSCLC, hepatocellular carcinoma, as well as palliation of patients with advanced solid tumors.
